Form 8-K - Current report:
SEC Accession No. 0001193125-21-195039
Filing Date
2021-06-21
Accepted
2021-06-21 16:06:18
Documents
14
Period of Report
2021-06-16
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d183984d8k.htm   iXBRL 8-K 30273
2 EX-99.1 d183984dex991.htm EX-99.1 24458
6 GRAPHIC g183984g01p01.jpg GRAPHIC 14732
  Complete submission text file 0001193125-21-195039.txt   210699

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20210616.xsd EX-101.SCH 2898
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20210616_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20210616_pre.xml EX-101.PRE 11864
7 EXTRACTED XBRL INSTANCE DOCUMENT d183984d8k_htm.xml XML 3540
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 211030535
SIC: 2834 Pharmaceutical Preparations